07.06.2016 • NewsElaine BurridgeGevo

Gevo Studies Strategic Alternatives

US renewables company Gevo is reviewing strategic alternatives for its future and has appointed Cowen & Company as a financial advisor. The two are seeking to engage with interested parties and investors. Gevo has not stated whether the review could include a potential sale.

“The board is thoroughly committed to exploring strategic and financial alternatives while simultaneously supporting management in the development of Gevo’s technology and business,” said Ruth Dreessen, chairman of Gevo’s board of directors. She added that pursuing both of these paths was in the best interests of the company’s stakeholders.

The company, which ended a four-year patent dispute with rival Butamax in August 2015, has a target to produce between 750,000 and 1 million gallons of isobutanol and 15 million gallons of ethanol this year at its facility in Luverne, Minnesota.

It said in its first-quarter 2016 report that it was working to make its processes more efficient and ramp up isobutanol production. The company had cash and cash equivalents of $8.7 million as of end March.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.